DK149850B - Analogifremgangsmaade til fremstilling af 5-(3,4-disubst. phenyl)-oxazolidinoner eller thiazolidinoner eller de tilsvarende thioner - Google Patents
Analogifremgangsmaade til fremstilling af 5-(3,4-disubst. phenyl)-oxazolidinoner eller thiazolidinoner eller de tilsvarende thioner Download PDFInfo
- Publication number
- DK149850B DK149850B DK536677AA DK536677A DK149850B DK 149850 B DK149850 B DK 149850B DK 536677A A DK536677A A DK 536677AA DK 536677 A DK536677 A DK 536677A DK 149850 B DK149850 B DK 149850B
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- mmol
- dimethoxyphenyl
- phenyl
- hydrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- -1 5- (3,4-disubstituted phenyl) oxazolidinones Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 238000001953 recrystallisation Methods 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- 125000005394 methallyl group Chemical group 0.000 claims description 4
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000007868 Raney catalyst Substances 0.000 claims description 2
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- HDFRDWFLWVCOGP-UHFFFAOYSA-N carbonothioic O,S-acid Chemical class OC(S)=O HDFRDWFLWVCOGP-UHFFFAOYSA-N 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 229910000510 noble metal Inorganic materials 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- 150000002148 esters Chemical class 0.000 description 25
- 239000000052 vinegar Substances 0.000 description 24
- 235000021419 vinegar Nutrition 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- WIUFFBGZBFVVDL-UHFFFAOYSA-N 2-amino-1-(3,4-dimethoxyphenyl)ethanol Chemical compound COC1=CC=C(C(O)CN)C=C1OC WIUFFBGZBFVVDL-UHFFFAOYSA-N 0.000 description 5
- FWUOYEHWFKJVPM-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-1,3-oxazolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1OC(=O)NC1 FWUOYEHWFKJVPM-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- JJBPZTLYONVMMO-UHFFFAOYSA-N 2-amino-1-(4-methoxy-3-phenylmethoxyphenyl)ethanol Chemical compound COC1=CC=C(C(O)CN)C=C1OCC1=CC=CC=C1 JJBPZTLYONVMMO-UHFFFAOYSA-N 0.000 description 4
- GPIDPQGNDCYNMV-UHFFFAOYSA-N 5-(3-hydroxy-4-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound C1=C(O)C(OC)=CC=C1C1OC(=O)NC1 GPIDPQGNDCYNMV-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- DPYYYGAUCSEYLU-UHFFFAOYSA-N 1-amino-2-(3,4-dimethoxyphenyl)pentan-2-ol Chemical compound CCCC(O)(CN)C1=CC=C(OC)C(OC)=C1 DPYYYGAUCSEYLU-UHFFFAOYSA-N 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- JTIPLNDENHDFNZ-UHFFFAOYSA-N 2-amino-1-(3,4-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(C(O)C(C)N)C=C1OC JTIPLNDENHDFNZ-UHFFFAOYSA-N 0.000 description 2
- KGLGVBPFBKSBCX-UHFFFAOYSA-N 2-hydroxy-2-(4-methoxy-3-phenylmethoxyphenyl)acetonitrile Chemical compound COC1=CC=C(C(O)C#N)C=C1OCC1=CC=CC=C1 KGLGVBPFBKSBCX-UHFFFAOYSA-N 0.000 description 2
- WSJBJAAZLUZIBN-UHFFFAOYSA-N 3-acetyl-5-(3,4-dimethoxyphenyl)-1,3-oxazolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1OC(=O)N(C(C)=O)C1 WSJBJAAZLUZIBN-UHFFFAOYSA-N 0.000 description 2
- VQVQZFHUXRSRBZ-UHFFFAOYSA-N 4-methoxy-3-phenylmethoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OCC1=CC=CC=C1 VQVQZFHUXRSRBZ-UHFFFAOYSA-N 0.000 description 2
- VYYWZBLVFMZEPW-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-1,3-thiazolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1SC(=O)NC1 VYYWZBLVFMZEPW-UHFFFAOYSA-N 0.000 description 2
- BUBOFKLTSLHVCD-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-5-propyl-1,3-oxazolidin-2-one Chemical compound C=1C=C(OC)C(OC)=CC=1C1(CCC)CNC(=O)O1 BUBOFKLTSLHVCD-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical group CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- SBMSBQOMJGZBRY-UHFFFAOYSA-N Propioveratrone Chemical compound CCC(=O)C1=CC=C(OC)C(OC)=C1 SBMSBQOMJGZBRY-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- GCMWHGRXCCOJPY-UHFFFAOYSA-N ethyl n-[2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]carbamate Chemical compound CCOC(=O)NCC(O)C1=CC=C(OC)C(OC)=C1 GCMWHGRXCCOJPY-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- KZROGFITRJWKSR-UHFFFAOYSA-N 2-(3-cyclopentyloxy-4-methoxyphenyl)-2-hydroxyacetonitrile Chemical compound COC1=CC=C(C(O)C#N)C=C1OC1CCCC1 KZROGFITRJWKSR-UHFFFAOYSA-N 0.000 description 1
- KTNGJAYBALUWMM-UHFFFAOYSA-N 2-amino-1-(3-cyclopentyloxy-4-methoxyphenyl)ethanol Chemical compound COC1=CC=C(C(O)CN)C=C1OC1CCCC1 KTNGJAYBALUWMM-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- QRAVQSUPXLYYFD-UHFFFAOYSA-N 3-(4-methoxy-3-phenylmethoxyphenyl)-1,3-oxazolidin-2-one Chemical compound C(C1=CC=CC=C1)OC=1C=C(C=CC=1OC)N1C(OCC1)=O QRAVQSUPXLYYFD-UHFFFAOYSA-N 0.000 description 1
- FZFWPURYSWKIRT-UHFFFAOYSA-N 3-cyclopentyloxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OC1CCCC1 FZFWPURYSWKIRT-UHFFFAOYSA-N 0.000 description 1
- SGPKGBKZKIFUKB-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-1,3-oxazolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1NC(=O)OC1 SGPKGBKZKIFUKB-UHFFFAOYSA-N 0.000 description 1
- CIOXIFWTLJGCOD-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-3-methyl-1,3-oxazolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1OC(=O)N(C)C1 CIOXIFWTLJGCOD-UHFFFAOYSA-N 0.000 description 1
- NDJGWGFOAAGHLD-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-4-methyl-1,3-oxazolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1C(C)NC(=O)O1 NDJGWGFOAAGHLD-UHFFFAOYSA-N 0.000 description 1
- FRZBUHRQAKOGNP-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-5-methyl-1,3-oxazolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1(C)OC(=O)NC1 FRZBUHRQAKOGNP-UHFFFAOYSA-N 0.000 description 1
- QIEFNVNAKZVPSU-UHFFFAOYSA-N 5-(3-cyclopentyloxy-4-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=C(C2OC(=O)NC2)C=C1OC1CCCC1 QIEFNVNAKZVPSU-UHFFFAOYSA-N 0.000 description 1
- PJCYTIMTAXWZPH-UHFFFAOYSA-N 5-(4-methoxy-3-phenylmethoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=C(C2OC(=O)NC2)C=C1OCC1=CC=CC=C1 PJCYTIMTAXWZPH-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 102100039845 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-8 Human genes 0.000 description 1
- 101710112841 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-8 Proteins 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001090 anti-dopaminergic effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- ZAENXHXQWSDUOG-UHFFFAOYSA-N benzene;iodine Chemical compound [I].C1=CC=CC=C1 ZAENXHXQWSDUOG-UHFFFAOYSA-N 0.000 description 1
- QUCWPNLLUCSDCK-UHFFFAOYSA-N benzyl N-[2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]carbamodithioate Chemical compound C(C1=CC=CC=C1)SC(NCC(O)C1=CC(=C(C=C1)OC)OC)=S QUCWPNLLUCSDCK-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- JJFPITWARCIURC-UHFFFAOYSA-N ethyl 5-(3,4-dimethoxyphenyl)-2-oxo-1,3-oxazolidine-4-carboxylate Chemical compound C(C)OC(=O)C1NC(OC1C1=CC(=C(C=C1)OC)OC)=O JJFPITWARCIURC-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- NVIFVTYDZMXWGX-UHFFFAOYSA-N sodium metaborate Chemical compound [Na+].[O-]B=O NVIFVTYDZMXWGX-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/16—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Description
149850
Opfindelsen angår en analog i fremgangsmåde til fremstilling af hidtil ukendte 5-(3,4-disubst. phenyl)-oxazolidinoner eller thiazolidinoner eller de tilsvarende thioner med den almene formel I
149850 2 GR?
RiG^I
(I),
Vs'53 i hvori R·. betegner Cj_g alkyl eller 03.7 cykloalkyl, 15 R? betegner hydrogen, C^.g alkyl, 03.7 cykloalkyl, phenyl, benzyl, allyl, 2-propynyl, methallyl eller tetrabydrofurany1, R3 betegner hydrogen, Ci_6 alkyl, eventuelt med 2 methoxygrup-per substitueret phenyl-Ci_2 alkyl, acetyl, benzyloxycarbonyl 20 eller phenyl carbamoyl, R4 betegner hydrogen eller Ci_g al kyl, R5 betegner hydrogen, methyl eller ethoxycsrbony1, og 25 X og Z hver for sig betegner oxygen eller svovl.
Forbindelserne med den almene formel I har et asymmetrisk car-bonatom og kan derfor både foreligge som racemater og som op- 20 tiske antipoder.
Forbindelserne, der er fremstillet ifølge opfindelsen, med den almene formel I besidder værdifulde farmakologiske egenskaber.
De udviser central depressive, antidopaminerge, antinociceptive o 5 og antikonvulsive virkninger og har dermed en vis lighed med neu-roleptika, såsom chlorpromazin eller haloperidol. Forbindelserne, der er fremstillet ifølge opfindelsen, afviger dog fra de klassiske neuroleptika ved en anderledes indvirkning på receptorafhængige, monoaminerge tilbagekoblingsmekanismer (forringelse af de ekstrapyrimidale bivirkninger).
3 149350
Forbindelserne, der er fremstillet ifølge opfindelsen, besiddder desuden kraftige phosphodiesterasehæmmende egenskaber og påvirker 5 dermed stofskiftet af cykliske nukleotider. Da kontrolleret cellevækst afgørende bliver reguleret af cykliske nukleotider. (Pastan et al., 1975) og i ukontrolleret prolifererende væv cykliske nukleotider delvis er formindsket (Ryan og Heidrick, 1974, Voorhees et al., 1974), egner forbindelserne sig til behandling af hyper-^ proliferative og med ukontrolleret cellevækst optrædende sygdomme, såsom Psoriasis, PolyCythæmia vere, Neuroblastom, immunologiske sygdomme, såsom Asthma bronchiale og thromboemboliske sygdomme, hvor der foreligger en forstyrrelse i stofskiftet af cykliske nukleotider (Tateson, J.E., Trist, D.G., Inhibition of adenosine 15 -31, 51-cyclic monophosphate phosphodiesterase by potential antiallergic compunds, Life Sci. 18, 153-162, 1976; De Gaetano, G., Pharmacology og plantelet aggregation; Pharmacol, Res. Commun. 7, 301-309, 1975).
20
Fra Journ. Med. Chem. bind 7 (1964), 178 kendes oxazolidino- ner. Som det fremgår af de efterfølgende forsøgsresultater, har de ifølge opfindelsen fremstillede forbindelser en uventet nyttig virkning i sammen!igning med de kendte strukturelt be-25 slægtede forbindelser. I den efterfølgende tabel er angivet den biologiske aktivitet af forbindelser bestemt i en modificeret muse-screeningstest ifølge Jrwin (S. Irwin, Psychophar-macologica (Berl.) 13 (1968) 222-251). Forbindelsen, der skal undersøges opløses eller suspenderes her i en 10 vægt% opløs-30 ning af Cremofor® EL. Denne opløsning indgives intraperi tonealt. Efter injektionen vurderes dyrene efter en forudbestemt skala, som tillader en vurdering af virkningen på musenes centralnervesystem. Der blev anvendt tre mus til hvert forsøg.
35 Resultaterne i tabellen viser den mindste virksommme dosis i mg pr. kg legemsvægt som endnu virker i mindst to af tre mus.
4 1Λ9850 (1) ' o · ifN »Λ ΙΑ ΙΑ tA tA tA ΙΑ Κ\ ΙΓ\
Ι|Η ο - ΙΑ Ο -ο - CM - CVJ »WOriOOOW ttfM Ο OJ CM Ο CM Ο CM -CM -CM -O -OOO
CQH 1-1 H HHCDriVDHiOrMOCMI^COrlii-lO
— ho hi o o o o oooo- O OO o M u oo ooooootno oooo o
U CO H HWWCOHiCMlf\ ] I CO tA CO CM I H
no- · λ» +.
'· tS --- . - · - - -τί -'· ΊΑ ' * 'ΙΑ ΙΑ ΙΑ ΙΑ '· - , - VO . · " ' ' · ΙΑ -i η ο cm οο-ο - cm - ; . ...ια · ό ο ο cm
Ofl Ο - Ο Ο CM Ο CM - CM Ο - Ο Ο Ο ΙΑ Ο -
. Ciji ft m i—1 VO Η H i H O ri tA 1 i-4 IA CM CO CM CM CO
£ \ . W-p — ·· . ...
m .
“ -H fA tA tA 7 IA VO IA - 03 i O r-1 O O - O CM O - IA 0.0 -O O O -
S -..O i: O - O O CM O IA - O O CM -OOOOOCM
.- V -§ ."g ti7 00 fA- CM ^ H 4 CM VO H U> <-4.H CO CM CO rt ^ r-C
Φ .'· --I ' ·" - > -- _;_, . ' ' _ Τί -- erf Μ Ι·Η - ^ «Α -ΙΑ m .ίο Ό Ο Ο O O Ο Ο Ο CM Ο CM Ο in 43 ft Ο Ο - Ο ΟΟιΑιΑΟΟΟ -Ο -Ο θ' 4-1 <a<D CO Η «-4 I HOJCMWrl^WVOCOVOCO I I ΙΑ .
ο Orl Λ /s λ <ΰ__-___ +J . · 03 ' · η ό α G Ο 03
1-4 -γΗ.-ΗΡ ΙΑ tA A tA fA
W g -PC! OOOOCMO CM- «—I O ι-t O O
P3 440 OlAlAO'-OlA-CMOO-O-O OO
2 Eh -d" r4 VO CO CM VO r4 tA ΙΑ ΓΑ r4 tA CO I if· tA
^ ‘ ' Φ 44 , * p·' (d 44 03 , ' S l! m N\ Ά IA tA ΙΑ IA tA K\
.j λπ Or4 OO — O CM CM - CM Η iHO O
-Jj5.h ° -OOCMOIA--CM - - O -o OtA
44 0 > HCVlHsCVlVDvOrlVOtA tA tA CM | CM
2 S-H Ό -P <D 4444 Pi td (d i -,--; ---EN“ fA-
•Μ H-4 ItK
K, jIt 3 7 _«· . =r =? f f K--O--jtM -- Ο O —---
B S O I
λ -p ώ m ft t*- 3 - cay o „ Λ cm 'cMsTaTaTn A] * p ? ? o
η ‘sT π sP
Y K OOO k/ΟΟΟΟΟΟϋΟΟΟΟΟΟΟ I lit Iiitiiiiiiiiiti o <—i--. -----------—— .. ......... .., «
$_J
£5 ^ pj ^ -s· in ο Γ'· =c c* ο η μ n c invor^cc
^ Ή t—4 ·—( < pH
--;—--;--149850 « ο
Ih Ο Ο Ο Ο « U ΙΛ Ο Ο Ο •Η Ο CM CM -S' W Η I Φ
So _ U x o o o X h o O I o a h CM CO I eo •a o β -rl • 1 B - Λ .
• O U Ο Ο ΙΛ o
. ·. p. ® ir\0 CM. -O
Ϊ5 * · ij __ _ —-—— - 0) • - 0 « ..· :·. Ό · "S O O I o ® o ir\ o i © o' C: »» cm -sr tTl Q- r~i X · Φ \ . ....... ..........— ------ -------- -----— Ό ίτ> · Ό.
fi · ? - β . · •I -H φ to « η Ο ο Ο -¾
Η -μ ft o . O 1.- · O . X
to (β® CM >4* I CO "β
Ο Ο H
Η Ό _____ ·Η JO) O' w > β a
CQ -rl ‘ 0 to -H
rtj +> -Η β β
Eh X -P β M
Φ +5 O irt Ο Ο Ο β
<H Ή - β Eh CM Ο Ο O -H
tO Ή Ό -S* Η -ί* i> Φ 0) M-l Φ Pi id β , .ω -· 0) φ h ’ +1 -X--1-...... ........ ............. ' ' O' a) to to β
4-1 Ό β -Η -P -H
4-1 . β Ο β Q)
ίΰ -Γ+ *rt O 44 II
CO £] -P 4-1 *H ΙΛ O O.
+)- Μ Ο t> «Μ Ο I Ο I
β - β g -rl Η I jf I
Ο Ό 4->
<44 φ Μ4 X
- ρβ ro cd _ ijtn ο ο η I *-----— ΙΛ ιι ιι u ιι 05 ^ Ν ^ Ν . - ι - Γ“\ of *? *? Γ__ -J*· /
05--X Ο Β X
05 ι ι Γ- 9 « - Ο Λ ---° < -· =τ< * ιι ζ x cm ζ X ο ·α «η JT «ο / « */ «= ri 05 w 05 Ο Ο CM £« °-\ / 11 ® Λ. Η U41 ι--riS ^ Γη] j ο i w« sy^y 4 s * o oi x x L J .x o'^r · .
η υ o S M w ι O -> K ιι o o ----s___
β O' O H CM
Z H CM CM CM
6 149850 På grund af de beskrevne virkninger kan forbindelserne, der er fremstillet ifølge opfindelsen i form af farmaceutiske præparater, anvendes til behandlingen af de førnævnte sygdomme.
5
Fremstillingen af de heri omhandlede hidtil ukendte forbindelser sker ifølge opfindelsen ved den i kravet definerede fremgangsmåde.
De anvendte opløsningsmidler er hensigtsmæssigt inaktive over for reaktanterne. Eksempelvis skal nævnes ethere såsan diethylether, glycoldimethylether eller diethylenglycoldimethylether, alifatiske og aranatiske hydrocarboner såsan hexan, benzen, toluen, xylen og mesitylen, men også alkoholer son methanol, ethanol, propanol og butanol samt dimethylsulfoxid, glycolmonanethylether og diethylenglycolmonattethylether.
15 Reaktionen gennemføres hensigtsmæssigt i varmen, men lykkes dog også som eksempelvis anført ved 10°C og ved stuetemperatur, hvorhos temperaturområdet fra 60-200eC fortrinsvis anvendes .
20 Ringslutningsreaktionen gennemføres fortrinsvis i nærværelse af en basisk katalysator. Egnede basiske katalysatorer er al-kalimetal- og jordalkalimetalcarbonater og specielt -alkohola-ter såsom natriummethylat og kaliumcarbonat. Egnede er imidlertid også organiske baser såsom pyridin, triethylamin, alka-25 limetal- og jordalkalimethalhydroxider såsom natriumhydroxid, specielt i det tilfælde hvor X' eller Y er halogen. I det tilfælde, hvor X' er halogen som f.eks. chlor, kan der også anvendes en basisk katalysator. Når X' og Y er imidazolrester, arbejdes der fortrinsvis ved stuetemperatur, hvorved dimethyl-30 formamid, tetrahydrofuran og methylenchlorid er velegnede som opløsningsmidler. Den eventuelt efterfølgende reduktive af-spaltning af benzyl gruppen i betydningen R2 kan ske med alle sædvanlige metalkatalysatorer, såsom f.eks. platin, palladium, rhodium eller nikkel, såvel i ren form som på bærematerialer, 35 såsom carbon, calciumcarbonat og bariumsulfat. Som opløsningsmiddel kan anvendes alle sådanne opløsningsmidler, som er inaktive over for reaktionsmidlerne under de i ovenrenstemmelse med opfindelsen anvendte betingelser. Eksemplevis skal nævnes organiske syrer såsom eddikesyre og propionsyre, lavere alko-40 holer såsom methanol og ethanol, estere såsom eddikeester, alifatiske, cykloali fatiske og aromatiske hydrocarboner såsom hexan, cyklohexan og benzen.
7 1498130
Den eventuelt efterfølgende N-acylering eller N-alkylering (R3 = H) sker ifølge i og for sig kendte metoder. Aminoforbindel-sen opløses således i et polært opløsningsmiddel og opvarmes i nærværelse af en saltdsanner med et alkyl- henholdsvis acylha-5 logenid eller acylanhydrid til 40 til 150°C. Som polære opløsningsmidler kan anvendes dimethylformamid, dimethylacetamid, tetrahydrofuran, dioxan samt alkoholer såsom ethanol og butanol. Egnede saltdannere er f.eks. natriumhydrid, kaliumcarbo-nat, alkalialkoholater såsom natriumethylat, kalium-tert.-bu-tylat osv. Omsætningen med halogenaryl, f.eks. jodbenzen kan også gennemføres uden opløsningsmiddel, fortrinsvis i nærværelse af kobberpulver.
De efterfølgende eksempler tjener til belysning af opfindel-15 sen.
Eksempel 1 5-(3-benzyloxy-4-methoxyphenyl1-2-oxazolidi non.
20 318,6 mmol 3-benzy1oxy-4-methoxybenzaldehyd opløses i 1200 ml ether. Hertil sættes en opløsning af 558 mmol kaliumcyanid i 300 ml vand ved stuetemperatur. Efter afkøling til 0°C dryppes 237 mmol 2N svovlsyre til den godt omrørte blanding, og reak-25 tionsblandingen omrøres i 12 timer ved stuetemperatur. Efter fraskilning af den vandige fase vaskes etheren flere gange med 50 ml halvmættet kogsaltopløsning og tørres kraftigt over calciumchlorid. Efter frafi 1 trering af tørringsmiddel og ef-tervaskning med to gange 100 ml ether, anvendes de forende fa-30 ser, som indeholder det rå 2-{3-benzyloxy-4-methoxyphenyl)-2-hydroxy-acetonitri 1, til næste trin.
På tilsvarende måde fremstilles der af 3,4-dimethoxybenzalde-hyd 2-(3,4-dimethoxyphenyl)-2-hydroxyaoetonitri let og af 3-cy-35 klopentyloxy-4-methoxybenzaldehyd 2-{3-cyklopentyloxy-4-me- thoxyphenyl)-2-hydroxyacetoni tri let.
1,3 mol 1 ithiumalumi niumhydrid suspenderes portionsvis i 1 liter absolut ether, og under kraftig omrøring idryppes 40 etheropløsningen af 2-(3-benzyloxy-4-methoxyphenyl)-2-hy- droxyacetonitri1 således, at der kun optræder en svag til- 8 149850 båge-SVåliftg. Efts»· Véd stuetemperatur natten over ti»dryppes under afkøling først 400 ml edikkeester og senere 600 ml vand. Det dannede bundfald frasuges derpå og resten eftervaskes to gange, hver gang med 200 ml ethanol/vand (1:1). Den samlede filtratmængde inddampes kraftigt og optages i 300 ml halvkon-centreret saltsyre. Denne opløsning ekstraheres to gange, hver gang 5 med 200 ml eddikeester. Eddikeesterfasen kasseres, og den saltsure opløsning afkøles og vaskes alkalisk med kaliumhydroxid (eventuelt udfældede aluminiumsalte suges fra) og udrystes tre gange, hver gang med 400 ml ether. De forenede organiske faser tørres, inddampes efter filtrering og omkrystalliseres fra eddikeester.
10
Den i et udbytte på 20% opnåede 2-amino-l-(3-benzyloxy-4-methoxyphe= nyl)-ethanol smelter ved 101-102°C.
På tilsvarende måde fremstilles af 2-(3,4-dimethoxyphenyl)-2-hydroxy= 15 acetonitril i et udbytte på 49% 2-amino-l-(3,4-dimethoxyphenyl)-etha= nol (smp. 80-81°C, benzen) og af 2-(3-cyklopentyloxy-4-methoxyphenyl)-2-hydroxyacetonitril i et udbytte på 70% 2-amino-l-(3-cyklopentyloxy-' 4-methoxyphenyl)-ethanol (olie).
2o 2-amino-l-(3-benzyloxy-4-methoxyphenyl)-ethanol kan også fremstilles på følgende måde: 50 mmol 3-benzyloxy-4-methoxybenzaldehyd og 55 mmol trimethylalylcya= nid opvarmes sammen med 0,567 mmol vandfri zinkjodid i 4 timer under 25 nitrogen og under udelukkelse af fugt til'90°C. Derpå optages i 15 ml absolut tetrahydrofuran, og denne opløsning dryppes til en suspension af-60 mmol lithiumaluminiumhydrid i 35 ml tetrahydrofuran. Efter en times opvarmning til 60°C oparbejdes som tidligere beskrevet. Efter omkrystallisation fra eddikeester isoleres 2-amino-l-(3-benzyloxy-4 30 methoxyphenyl)-ethanol med smeltepunkt 100-102°C i et udbytte på 30%.
36 mmol 2-amino-l-(3-benzyloxy-4-methoxyphenyl)-ethanol suspenderes med 50 mmol natriummethylat og 91,4 mmol diethylcarbonat i 120 ml absolut toluen og opvarmes i 2 timer til 110°C badtemperatur under 35 udelukkelse af fugt, hvorhos methanol og ethanol destillerer over.
Derpå afdestilleres toluenen til sidst i oliepumpevakuum. Resten optages i 150 ml chloroform og fordeles i forhold til 100 ml vand. Vandfasen ekstraheres to gange, hver gang med 150 ml chloroform, de forenede chloroformekstrakter vaskes med 100 ml vand, tørres, filtreres og inddampes og omkrystalliseres fra eddikeester. Der fås 5-(3-benzyl= 9 U98B0 oxy-4-methoxypheny1) -2-oxa zolidinon med smeltepunkt 132-133°C (91% udbytte).
Eksempel 2 På tilsvarende måde som beskrevet i eksempel 1 fremstilles af de til-5 svarende aminoalkoholer de i den følgende tabel anførte oxazolidinoner.
R1 R2 R3 r4=r5 Ombytte Smp. <°C) (%) r ' ' liseret fra 10 -CH3 -CH3 -H -H 63 114-117 Methanol -CH3 -CH3 -CH3 -H 41 132-134 Ethanol -CEL —/ -H -H 45,8 141-143 Eddikeester/ '— ether 15 -CHo -H -H 52 111-112,5 Eddikeester/ '—J ether —----- - .....
Eksempel 3 20 88,3 mmol 2-amino-l-(3-benzyloxy-4-methoxyphenyl)-ethanol opløses i 200 ml absolut tetrahydrofuran og behandles under udelukkelse af fugtighed med 92,6 mmol carbonyldiimidazol. Den klare opløsning omrøres natten over ved stuetemperatur. Efter afdestillation af tetrahydro= 2^ furan optages i 300 ml eddikeester, udrystes to gange med IN saltsyre og vaskes derpå neutral med mættet natriumchloridopløsning, tørres, filtreres og inddampes.
Efter omkrystallisation fra eddikeester fås et udbytte på 66% 5—(3— 3q benzyloxy-4-methoxyphenyl)-2-oxazolidinon med smeltepunkt 83-91°C.
Eksempel 4 5-(3-hydroxy-4-methoxyphenyl)-2-oxazolidinon.
40,6 mmol 5-(3-benzyloxy-4-methoxypheny1)-2-oxazolidinon opløses i 700 ml ethanol og hydrogeneres i nærværelse af 8 g Raney-nikkel (B 113, Fa. Degussa, Frankfurt) ved stuetemperatur under et nitrogen- 35 10 149850 tryk på 100 atmosfære i 2,2 timer. Efter frafiltrering af katalysatoren inddampes der, og resten omkrystalliseres fra methanol. Der fås 6,74 g 5-(3-hydroxy-4-methoxyphenyl)-2-oxazolidinon med smeltepunkt 157-160°C (methanol).
Eksempel 5 5 5-(3-cyklopentyloxy-4-methoxyphenyl)-2-oxazolidinon.
7,2 mraol 5-(3-hydroxy-4-methoxyphenyl)-2-oxazolidinon opløses i 10 ml absolut dimethylformamid og omrøres med 7,9 mmol natriumhydrid i en time 10 o ved 50 C. Efter afkøling behandles med 8,6 mmol cyklopentylbromid og derpå omrøres i 2 timer ved 80°C. Efter endt reaktion fjernes dimethyl= formamidet i vakuum ved 40°C. Resten optages i 100 ml 2N natriumhydroxid og ekstraheres tre gange med 150 ml chloroform. De forenede chloroform-^ faser vaskes med vand, tørres, filtreres og inddampes. Resten omkrystalliseres fra eddikeester/ether.I et udbytte på 70% fås 5-(3-cyklo= pentyloxy-4-methoxyphenyl)-2-oxazolidinon med smeltepunkt 111-112°C.
Eksempel 6 20
Ifølge den i eksempel 5 beskrevne fremgangsmåde fremstilles af 5—(3— hydroxy-4-methoxyphenyl)-2-oxazolidinon og halogenidet eller tosylatet
"v O >1 C
R X"de i den følgende tabel anførte forbindelser (R-R - R = H). 1 tabellen betyder DMF = dimethylformamid * Petr. = petroleumsether Chlf. = chloroform
Tos. = tosylat
NaH = natriumhydrid NaOEt = natriumethylat 11 149850 ' Μ Μ (1) μ μ Μ 0) g μ Μ S-* ^ \ QJ Q) Ο S ·Η 0) 0) (1) <1) jH'dgee ·η +> g § § § c 3 -Η ·Η ·Η ·Η -μ ·Η Ή ·Η -Η 5 +j 4J +)+)+> ιη-μ-Ρ +> +3 (ΰ ο - ΰ Μ Μ Μ CM "3* (Ο CO CO ΙΟ (1)\\\\\\ \ \ \ ftUUUUUUU υ υ εοοοοοοο ο ο (1)0000000 ο ο Ε-ινοοοοοιοονονο in γ~~ Ν 10 f-H Η Μ 1 Αυ . . ο ο α> μ I \!η \κ .ric ·Ηβ41+) •Η μ Μ μ .μ μ +> IH« Ή <0 «3 0) η ωω 0)0)0)0) ιβ ρ: <ο ρ: α) & η +>+> +> α -μ α< μ -μ μ -μ α>
Π) Η 03 03 (Ο 03 Οι 0) —- &> 0) AS
+> ·Η Ο 0) Φ 0) Φ Ο g Η Ο S
03 C 0) 0) = = Ο) Φ +>\···μ\Ό >,+> <0 as χ as as 2 ·<λ 5
Ud) Λ ·Η ·Π |Η -Η § ^ Αίμ+ΐΌΌ ΌΌ ΟΗ Ο»—ι -, c 60)0)¾¾ ¾ ¾ μ ρι μ ρ! ρ 15 δ in a Η Η_Η Ρ_S ϋ Κ ϋ Ο .
U
or~oor~moor~ ο —'γΗΟγΗ ο γ- οο ** ο Η rH rH Η Η 0) Η
• I I I I I I I -Η I
Qj^cot^· νο ρ> Η οο εΗΟΟΟΓ'ΟΟ«^ Ο Ο.
Ρ rH rH rH ιΗ rH
20 μι__._—-- Μ 0) -μ ρ +)« >ι 0ν ο *η< ο ro ο ο r·» ιο
<| Λ'-'ΟΟΠ (Μ ό1 Γ-- οο ^ CM
¾
Eh Ρ____ 25 s μ μ μ μ μ μ Η ηη
XPPQffl Ρ Ρ Ρ Ρ U ρ! O
_ (¾_ , ro ro co co ro ro ro ro o hppppppp p p DSOUOUOOO u u
I I I I I I I I I
30 co ro co
PPM CM
u U U ro p CM ro
l\/ PUPPP
cm \P/ O II U U O
— O ,_, I P HI \' / I /ΛI
™ cm I ro o u O I () I
« co P cm [ ~ | I I
PUPL CM CM CM CM 1
U — U 1-\ P P P P I
III ' u O u u
— I I I
35 ---- 01 tr> c \
•HHPPP P PP P P H
sp 0) cd ces «3 Φ cd cd tf rO o -μ
03¾^¾¾ S SS S S ζ P
^1¾ \ \\ \\ \\ \ (0 o H -H fe fe fe S fe fe fe fe fQ(0 a g s s s g as s a +; s
OQQQQQQP P P
149850
Eksempel 7 ^2 5-(3,4-dimethoxyphenyl)-2-oxazolidinthion og 5 5-(3,4-dimethoxyphenyl)-2-thiazolidinon.
45 mmol 2-amino-l-(3,4-dimethoxyphenyl)-ethanol opløses i 65 ml absolut dimethylsulfoxid og behandles i rækkefølge med 1,8 g pulveriseret kaliumhydroxid og 1,4 ml earbondisulfid ved 10°C. Derpå omrøres reak-10 tionsblandingen i 2 1/2 time under udelukkelse af fugtighed. Efter fjernelse af dimethylsulfoxid under vakuum behandles resten med 100 ml vand og ekstraheres tre gange med 100 ml chloroform. De forenede chloro-formfaser tørres over vandfri magnesiumsulfat, filtreres, og inddampes. Resten kromatograferes over 125 g kiselgel med chloroform/methanol 15 (96:4). Efter omkrystallisation af de tilsvarende fraktioner fra metha= nol fås i et udbytte på 9% 5-(3,4-dimethoxyphenyl)-2-oxazolidinthion med smeltepunkt 177-178°C samt 6% 5-(3,4-dimethoxyphenyl)-2-thiazoli= dinon med smeltepunkt 167-169°C.
20 Eksempel 8 5-(3,4-dimethoxyphenyl)-2-thiazolidinon.
10 mmol 2-amino-l-(3,4-dimethoxyphenyl)-ethanol opløses i 6 ml pyridin 25 og behandles under afkøling til 0°C dråbevis med 11 mmol carbondisul= fid i 10 mmol triethylamin, hvorved temperaturen stiger kraftigt. Der omrøres i en time ved 0°C>og derpå tildryppes ved den samme temperatur 10 mmol benzylchlorid. Efter omrøring natten over ved 0°C optages blandingen i 40 ml 3N svovlsyre og ekstraheres tre gange med 50 ml 30 chloroform hver gang. De forenede chloroformfaser vaskes i rækkefølge med natriumhydrogencarbonat og vand, tørres, filtreres og inddampes.
Den spontant krystalliserende rest omkrystalliseres fra benzen og eddikeester. I kvantitativt udbytte fås [2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]-dithiocarbaminsyrebenzylester med smeltepunkt 130-132°C.
35
Til 6,07 mmol [2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]-dithiocarbamin= syrebenzylester i 50 ml absolut ether tildryppes ved 5°C 2,14 mmol phosphortribromid. Efter 20 timers omrøring af stoffet ved 5°C tildryppes under afkøling 10 ml methanol/vand, således at temperaturen ikke overstiger 20°C. Derpå røres reaktionsblandingen forsigtigt i 20 ml 13 149850 natriumhydrogencarbonatopløsning. Der ekstraheres tre gange hver gang med 50 ml chloroform, og de forenede organiske faser vaskes i rækkefølge med 50 ml natriumhydrogencarbonatopløsning og 50 ml vand, tørres, filtreres og inddampes. Der fås 2-benzylthio-5-(3,4-dimethoxyphenyl-l,3-5 thiazol-2-in som en olie i et udbytte på 80%.
Denne olie opløses i 20 ml ethanol, behandles med 20 ml 6N saltsyre og koges i 4 timer under tilbagesvaling. Efter inddampning optages resten i 25 ml ethanol, behandles med 19 ml IN natriumhydroxid og omrøres i 10 tre timer ved stuetemperatur. Reaktionsblandingen neutraliseres derpå med 2N saltsyre, ethanolet fjernes og der udrystes tre gange hver gang med 100 ml chloroform. Chloroformfasen vaskes med vand, tørres og inddampes. Resten kromatograferes over 50 g kiselgel med chloroform/me= thanol (96:4) som elueringsmiddel.De tilsvarende fraktioner omkrystallise-15 res fra methanol, hvorved der fås 50% 5-(3,4-dimethoxyphenyl)-2-thia= zolidinon med smeltepunkt 167-169°C.
Eksempel 9 20 5-(3,4-dimethoxyphenyl)-2-oxazolidinon-3-carboxylsyreanilid.
0,5 mmol 4-(3,4-dimethoxyphenyl)-2-oxazolidinon opvarmes i 3 ml phenyl= isocyanat i 3 timer til 160°C. Efter afkøling inddampes reaktionsblandingen i vakuum, og der kromatograferes over 50 g kieselgel med cyklo= 25 hexan/eddikeester (1:1). Efter omkrystallisation af de tilsvarende fraktioner fra eddikeester fås i et udbytte på 60% 5-(3,4-dimethoxyphenyl)-2-oxazolidinon-3-carboxylsyreanilid med smeltepunkt 175-182°C.
Eksempel 10 30 100 mmol 2-amino-l-(3,4-dimethoxyphenyl)-ethanol opløses i 100 ml chloroform. Efter afkøling til 0°C tildryppes en opløsning af 100 ml phosgen i 100 ml chloroform så langsomt, at den indre temperatur ikke overstiger 5°C. Efter en times omrøring ved 5-10°C tildryppes 200 ml pyridin i 100 ml chloroform;og der omrøres i 3 timer. Efter vaskning af den organiske fase med halvmættet kogsaltopløsning inddampes og omkrystalliseres fra methanol. Der fås et udbytte på 75% 5-(3,4-di= methoxyphenyl)-2-oxazolidinon med smeltepunkt 114-117°C.
Eksempel 11 14 149850 5-(3,4-dimethoxyphenyl)-2-oxazolidinon.
5 mmol 2-amino-l-(3,4-dimethoxyphenyl)-ethanol opløses i 5 ml 2N natriumhydroxid. Den til 0°C afkølede opløsning behandles dråbevis med 10 mmol chlormyresyreethylester. Efter endt tilsætning omrøres 5 i 30 minutter ved 0°C. De dannede krystaller suges fra, vaskes med vand og tørres. X et udbytte på 86% fås 2-(3,4-dimethoxyphenyl)-2-hydroxyethylcarbaminsyreethylester med smeltepunkt 90-92°C.
3 mmol 2-(3,4-dimethoxyphenyl)-2-hydroxyethylcarbaminsyreethylester 10 suspenderes med 4 mmol natriummethylat i 12 ml toluen og opvarmes i 2 timer til 110°C badtemperatur under udelukkelse af fugtighed. Derved afdestilleres methanol og ethanol. Derpå fjernes toluenet i vakuum, resten optages i 50 ml chloroform og fordeles over for 10 ml vand.
Efter tørring, filtrering og inddampning af den organiske fase omkry-15 stalliseres fra methanol. I et udbytte på 80% fås 5-(3,4-dimethoxy= phenyl)-2-oxazolidinon med smeltepunkt 114-117°C.
Eksempel 12 20 3-acetyl-5-(3,4-dimethoxyphenyl)-2-oxazolidinon.
8,9 mmol 5-(3,4-dimethoxyphenyl)-2-oxazolidinon behandles med 10 ml eddikesyreanhydrid og 5 ml pyridin og opvarmes i 5 timer til 100°C.
Efter inddampning omkrystalliseres fra eddikeester. I et udbytte på 25 73% fås 3-acetyl-5-(3,4-dimethoxyphenyl)-2-oxazolidinon med smelte punkt 175-182°C.
Eksempel 13 30 5- (3,4-dimethoxyphenyl)-5-propyl-2-oxazolidinon.
56 mmol 3,4-dimethoxybutyrophenon i 61,4 mmol trimethylsilylcyanid under tilsætning af 200 mg(627 mmol) vandfri zinkjodid opvarmes i 4 timer til 90°C under nitrogen og udelukkelse af fugtighed. Reaktions-35 blandingen optages i 15 ml absolut tetrahydrofuran og dryppes til en suspension af 60 mmol lithiumaluminiumhydrid i 35 ml absolut tetrahy= drofuran, opvarmes i en time under nitrogen til 60°C,og lithiumalumi= niumhydrid overskud dekomponeres ved tildrypning af eddikeester og vand. Bundfaldet frasuges over kiselgel, eftervaskes omhyggeligt med 15 149850 ethanoljog moderluden inddampes. Resten optages i eddikeester, syrnes med 4N saltsyre og udrystes. Den vandige fases pH-værdi indstilles på 9 med natriumcarbonat, hvorpå der mættes med kog .salt og ekstraheres med chloroform. Chloroformfasen vaskes neutral med mættet kogsaltop- .
løsning, og opløsningsmidlet afdestilleres efter tørring over natrium* 5 sulfat. I et udbytte på 75,5% fås 5-amino-4-(3,4-dimethoxyphenyl)-4-pentanol som en olie. En analyseprøve i form af hydrochlorid smelter ved 175-176°C.
17,35 mmol 5-amino-4-(3,4-dimethoxyphenyl)-4-pentanol opløses i 10 ml absolut dimethylformamid og omsættes med 18,3 mmol 98 %ig carbonyldi-imidazol i 100 ml absolut tetrahydrofuran i 4 dage ved stuetemperatur under udelukkelse af fugtighed. Efter afdestillation af opløsningsmidlet optages resten i eddikeester, udrystes to gange med IN saltsyre og vaskes neutral med mættet kogsaltopløsning. Den opnåede olie renses 15 over en kiselgelsøjle (350 g) i systemet chloroform/methanol 30:1. I et udbytte på 81/7% fås 5-(3,4-dimethoxyphenyl)-5-propyl-2-oxazolidinon som en olie.
20 Eksempel 14 5-(3,4-dimethoxyphenyl)-5-methyl-2-oxazolidinon.
På tilsvarende måde som beskrevet i eksempel 13 fås af 3,4-dimethoxy= acetophenon i et samlet udbytte på 30% 5-(3,4-dimethoxyphenyl)-5-25 q methyl-2-oxazolidinon med smeltepunkt 98-101 C.
Eksempel 15 10 mmol 5-(3,4-dimethoxyphenyl)-2-oxazolidinon opløses i 20 ml absolut dimethylformamid og behandles med 11 mmol natriumhydrid. Derpå omrøres i 40 minutter ved 40°C. Efter afkøling tildryppes 20 mmol methyljodid i 5 ml dimethylformamidjog efter endt tilsætning omrøres i 6 timer ved 50°C. Efter fjernelse af dimethylformamid optages i chloroform, vaskes først med en ringe mængde vand og derpå med mættet kogsaltopløsning, 35 tørres, filtreres og inddampes. Resten kromatograferes over 60 g kiselgel med chloroform/methanol (96:4) som elueringsmiddel. Efter omkry-stallisation fra ethanol fås i et udbytte på 60% 5-(3,4-dimethoxyphenyl)- 3-methyl-2-oxazolidinon med smeltepunkt 132-133°C.
16
Eksempel 16 U9850 5-(3,4-dimethoxyphenyl)-2-oxazolidinon-3-carboxylsyrebenzylester.
6,25 mmol 5-(3,4-dimethoxyphenyl)-2-oxazolidinon opløses i 30 ml dioxan og behandles med 6,25 ml (12,50 mmol) 2N natriumhydroxid.
5 Ved 4°C behandles der med 12,5 ml carbobenzoxychlorid, og der omrøres i 4 timer ved denne temperatur.
Efter behandling med 50 ml 2N natriumhydroxid ekstraheres tre gange hver gang med 50 ml eddikeester. Eddikeesterfasen vaskes en gang med 10 50 ml 2N natriumhydroxid og to gange med 50 ml vand hver gang, tørres over "Sikkon" ® , filtreres og inddampes. Efter fjernelse af endnu tilstedeværende carbobenzoxychlorid ved 100°C og 1 torr omkrystalliseres resten fra eddikeester/petroleumsether og herved fås et udbytte -på 64%~ af 5- (3,4-dimethoxypl^yiy-2-oxazolidinon-l-carboxylsyrébenzylester med smeltepunkt 124-126°C.
Eksempel 17 5-(3,4-dimethoxyphenyl)-2-oxazolidLnon-3-carboxylsyreethylester.
20 5 mmol 5-(3,4-dimethoxyphenyl)-oxazolidinon blandes i 20 ml toluen (absolut) med 10 mmol triethylamin ved 0°C under udelukkelse af fugtighed
Blandingen behandles med 10 mmol chlormyresyreethylester, koges i 4 timer under tilbagesvaling og henstår natten over. Det udkrystalli-25 serede produkt suges fra og koges endnu en gang med 7,6 mmol triethyl= amin og 7,6 mmol chlormyresyreethylester. Det udkrystalliserede produkt suges igen fra. De forenede filtrater inddampes. Ved kromatografi af resten over 80 g kiselgel med cyklohexan/eddikeester (1:1) som eluerings-middel fås et udbytte på 43% 5-(3,4-dimethoxyphenyl)-2-oxazolidinon-1- A Λ carboxylsyreethylester med smeltepunkt 181-185°C.
Eksempel 18 På tilsvarende måde som beskrevet i eksempel 15 fremstilles af 5-(3,4-35 dimethoxyphenyl)-2-oxazolidinon de i den følgende tabel anførte oxazo= lidinoner: 149850 17 1 2 3 4 ς R R R R =¾3 Udbytte Smp. Omkrystallisation fra: CH- CEL isopropyl H 47 66-67°C Eddikeester/petroleums- ether 5 o CH-> CH, -CH9-0 H 66 75-76 C Eddikeester/petroleums- ether CHo CH, -CH0-CH„ H 40 77-78°C Eddikeester/petroleums- -3 * \ Δ ether 10 \/*voch3 och3
Eksempel 19 15 5-(3,4-dimethoxyphenyl)-4-methyl-2-oxazolidinon.
5,5 mmol 2-amino-l-(3,4-dimethoxyphenyl)-propanol opløses i 50 ml chloroform og omrøres med 1,05 g (6,5 mmol) carbonyldiimidazol i ?Ω 2 timer under udelukkelse af fugtighed. Efter henstand natten over ekstraheres med 50 ml destilleret vand, tørres, filtreres og inddampes. Efter kromatografi af resten over 50 g kiselgel med chloroform/ methanol (95:5) som elueringsmiddel og omkrystallisation fra eddike= ester/petroleumsether fås i et udbytte på 24% 5-(3,4-dimethoxyphenyl)-^ 4-methyl-2-oxazolidinon med smeltepunkt 98-99°C.
Udgangsmaterialet 2-amino-l-(3,4-dimethoxy)-propanol fremstilles på følgende måde:
Til 100 mmol 3,4-dimethoxypropiophenon i 160 ml methylenchlorid til-dryppes ved stuetemperatur 10 ml sulfurylchlorid i 80 ml methylen= chlorid. Derpå omrøres yderligere ved stuetemperatur i 3 1/2 time.
Efter fjernelse af opløsningsmiddel og omkrystallisation af resten fra cyklohexan/petroleumsether fås et udbytte på 89% 2'-chlor-3,4- 35 o dimethoxypropiophenon med smeltepunkt 56-57 C.
43,86 mmol 2'-chlor-3,4-dimethoxypropiophenon opløses i 230 ml acetone og i 7 dage omrøres med 437 mg kaliumj'odid og 87,72 mmol dibenzylamid under udelukkelse af fugtighed. Der fortyndes til 1 liter med diethylether, filtreres og inddampes. Resten fratages på kiselgel og 18 149850 kiselgelen udrøres først med chloroform og derpå med ethanol og der frasuges. Chlorofomfasen chromatograferes over 500 g kiselgel med chloroform som elueringsmiddel,og herved fås et udbytte på 49% 2'-N,N-dibenzylamino-3,4-dimethoxypropiophenon som en olie.
C
12,39 g (31,8 mmol) 2'-N,N-dibenzylamino-3,4-dimethoxypropiophenon opløses i 75 ml isopropanol og behandles med 1,33 g (35,05 mmol) natriumboranat. Efter en times omrøring ved stuetemperatur opvarmes i 2 timer under tilbagesvaling. Efter afkøling frasuges blandingen, og resten udkoges med eddikeester. Efter filtrering udkrystalliseres ^ af filtratet i et.udbytte på 59% 2'-(Ν,Ν-dibenzylamino)-1-(3,4-di= methoxyphenyl)-propanol med smeltepunkt 151-152°C.
13,2 mmol af dibenzylforbindelsen hydrogeneres i 50 ml ethanol p.a.
med 2,64 g pallalium-på-carbon (10%) i 3 timer ved 90°C under 10 ato 15 hydrogenatmosfære. Efter frasugning inddampes og omkrystalliseres fra ethanol. I et udbytte på 64% fås 2-amino-l-(3,4-dimethoxyphenyl)-propanol med smeltepunkt 131-132°C.
Eksempel 20 20 5-(3,4-dimethoxyphenyl)-2-oxo-oxazolidin-4-carboxylsyreethylester.
6 mmol 2-amino-4-(3,4-dimethoxyphenyl)-3-hydroxypropionsyreethylester omrøres med 12 mmol carbonyldiimidazol i 60 ml chloroform i 4 timer 25 ved stuetemperatur under udelukkelse af fugtighed. Derpå ekstraheres en gang med 50 ml vand, tørres natten over over silicagel, filtreres og inddampes. Resten kromatograferes over 130 g kiselgel med chloro= form/methanol (90:10) som elueringsmiddel. Ved omkrystallisation fra eddikeester/ethanol fås et udbytte på 34% 5-(3,4-dimethoxyphenyl)-2-3 0 oxooxazolidin-4-carboxylsyreethylester med smeltepunkt 188-189°C.
Udgangsmaterialet 2-amino-4-(3,4-dimethoxyphenyl)-3-hydroxypropionsyreethylester fremstilles på følgende måde: 35 44,37 mmol 3,4-dimethoxyglycidsyreethylester (fremstillet ifølge W. Schneider· et al., Arch. Pharm. 299, 817 (1966)) koges med 97,61 mmol dibenzylamin i 100 ml ethanol i 4 1/2 time under tilbagesvaling og under udelukkelse af fugtighed. Efter henstand i 3 dage ved stuetemperatur inddampesj og resten kromatograferes over 400 g kiselgel med chloroform/methanol (98:2) som elueringsmiddel. Kromatografi igen af de tilsvarende forenede fraktioner giver et udbytte på 89% 2-N,N-
Claims (2)
149850 dibenzyl-4-(3,4-dimethoxyphenyl)-3-hydroxypropionsyreethylester som en olie. 22,2 mmol
2-N,N-dibenzylamino-4-(3,4-dimethoxyphenyl)-3-hydroxypropion= ethylester hydrogeneres med 4,44 g palladium-på-carbon 10 %ig i 100 ml 5 udenatureret ethanol i 3 timer ved 90°C under 10 ato hydrogentryk. Efter frasugning af katalysatoren inddampes. Efter omkrystallisation fra udenatureret ethanol fås i et udbytte på 80% 2-amino-4-(3,4-dime= thoxyphenyl)-3-hydroxypropionsyreethylester med smeltepunkt 211-212 C (dekomponering). 10 Patentkrav. A nal og i fremgangsmåde til f rems ti Tling af 5-(3,4-disubst. phenyl )-oxazolidinoner eller thiazolidinoner eller de tilsvarende 15 thioner med den almene formel I 0R2 Rl° ^ ^----:---Rg (I), X N —R s 25 'X/' 7 hvori Rj betegner C^-6 alkyl eller Cø.y cykloalkyl, 3 0 ° R2 betegner hydrogen, Cj_g alkyl, c3_y cykloalkyl, phenyl, benzyl, ally!, 2-propynyl, methallyl eller tetrahydrofuranyl, R3 betegner hydrogen, Cj-g alkyl, eventuelt med 2 methoxygrup-per substitueret phenyl-Ci_2 alkyl, acetyl, benzyloxycarbonyl 35 eller phenyl carbamoyl, betegner hydrogen eller C-|_g alkyl. 149850 rg betegner hydrogen, methyl eller ethoxycarbony1, og X og Z hver for sig betegner oxygen eller svovl, kendetegnet ved, at man omsætter 2-amino-1-(3,4-disubst. 5 phenyl}-ethano 1 er med den almene formel ΪΓ 0R2 ' ^-Η (II) H0 hnr3* hvori R-i# R^ og R5 har ovennævnte betydning, og R2' er Cj_g alkyl, C3_7 cykloalkyl, phenyl, benzyl, allyl, 2-propynyl, me-thallyl eller tetrahydrpfurany1 og Rs'er hydrogen, C-|_g alkyl eller eventuelt med 2 methoxygrupper substitueret phenyl-Ci_2 alkyl, med carbonsyre- eller thiocarbonsyrederivater med den almene formel .X· 0 = (III) 25 eller S - c {111 a) "'^Y hvori X' o g Y sanmen betegner svovl eller hver for sig'betegner chlor, 3q brom, imidazolyl eller · OR (hvor R betegner alkyl, aryl eller aralkyl, eller hvor de to grupper R sammen betegner alkylen) i et.inaktivt opløsningsmiddel, fortrinsvis i nærværelse af en basisk katalysator, og derpå cm'ønsket emdanner en franstillet forbindelse, hvori R2 er benzyl til en forbindelse, hvori R2 er hy-35 drogen, ved reduktion med Raney-nikkel eller med en ædelmetalkatalysator og cm ønsket emdanner en'fremstillet forbindelse hvori er hydrogen til en forbindelse, hvori R2 er Ci_g alkyl, 03.7 cykloalkyl, allyl, 2-propynyT, methallyl eller« tetrahydrofuranyl
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2655369 | 1976-12-03 | ||
| DE19762655369 DE2655369A1 (de) | 1976-12-03 | 1976-12-03 | 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung |
| DE2745320 | 1977-10-05 | ||
| DE19772745320 DE2745320A1 (de) | 1977-10-05 | 1977-10-05 | 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung ii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK536677A DK536677A (da) | 1978-06-04 |
| DK149850B true DK149850B (da) | 1986-10-13 |
| DK149850C DK149850C (da) | 1987-04-27 |
Family
ID=25771221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK536677A DK149850C (da) | 1976-12-03 | 1977-12-02 | Analogifremgangsmaade til fremstilling af 5-(3,4-disubst. phenyl)-oxazolidinoner eller thiazolidinoner eller de tilsvarende thioner |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPS5382777A (da) |
| AT (1) | AT357529B (da) |
| AU (1) | AU519994B2 (da) |
| CA (1) | CA1097657A (da) |
| CH (1) | CH635578A5 (da) |
| CS (1) | CS199694B2 (da) |
| DD (1) | DD133667A5 (da) |
| DK (1) | DK149850C (da) |
| FR (1) | FR2372814A1 (da) |
| GB (1) | GB1588639A (da) |
| GR (1) | GR64964B (da) |
| HU (1) | HU175676B (da) |
| IE (1) | IE46435B1 (da) |
| IL (1) | IL53520A (da) |
| IT (1) | IT1089341B (da) |
| LU (1) | LU78616A1 (da) |
| NL (1) | NL7713153A (da) |
| SE (1) | SE441446B (da) |
| SU (1) | SU888821A3 (da) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2701215C2 (de) * | 1977-01-13 | 1982-10-14 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Thiazolin-2-thionen |
| US4348393A (en) * | 1978-06-09 | 1982-09-07 | Delalande S.A. | N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones |
| DE3438839A1 (de) * | 1984-10-19 | 1986-04-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Pharmazeutische praeparate |
| US5459145A (en) * | 1988-01-19 | 1995-10-17 | Pfizer Inc. | Calcium independent camp phosphodiesterase inhibitor antidepressant |
| WO1987006576A1 (en) * | 1986-04-29 | 1987-11-05 | Pfizer Inc. | Calcium independent camp phosphodiesterase inhibitor antidepressant |
| JPH01135098U (da) * | 1988-03-11 | 1989-09-14 | ||
| WO1991007177A1 (en) * | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders |
| US5461056A (en) * | 1992-05-08 | 1995-10-24 | Pfizer Inc. | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders |
| GB9212673D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
| GB9222253D0 (en) * | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| GB9226830D0 (en) * | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| US5622977A (en) * | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
| GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| ATE260911T1 (de) * | 1993-12-22 | 2004-03-15 | Celltech R&D Ltd | Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe |
| GB9326173D0 (en) * | 1993-12-22 | 1994-02-23 | Celltech Ltd | Chemical compounds and process |
| US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
| US5786354A (en) * | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
| GB9412573D0 (en) * | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| GB9412672D0 (en) * | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9526246D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9526245D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9625184D0 (en) * | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
| WO1998028281A1 (en) | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9713087D0 (en) * | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
-
1977
- 1977-11-28 SU SU772546252A patent/SU888821A3/ru active
- 1977-11-29 NL NL7713153A patent/NL7713153A/xx not_active Application Discontinuation
- 1977-12-01 DD DD7700202354A patent/DD133667A5/xx unknown
- 1977-12-01 LU LU78616A patent/LU78616A1/xx unknown
- 1977-12-01 IT IT30254/77A patent/IT1089341B/it active
- 1977-12-01 SE SE7713635A patent/SE441446B/xx not_active IP Right Cessation
- 1977-12-02 IE IE2446/77A patent/IE46435B1/en not_active IP Right Cessation
- 1977-12-02 CA CA292,273A patent/CA1097657A/en not_active Expired
- 1977-12-02 CH CH1477977A patent/CH635578A5/de not_active IP Right Cessation
- 1977-12-02 IL IL53520A patent/IL53520A/xx unknown
- 1977-12-02 DK DK536677A patent/DK149850C/da not_active IP Right Cessation
- 1977-12-02 HU HU77SCHE632A patent/HU175676B/hu not_active IP Right Cessation
- 1977-12-02 GB GB50350/77A patent/GB1588639A/en not_active Expired
- 1977-12-02 AU AU31175/77A patent/AU519994B2/en not_active Expired
- 1977-12-02 JP JP14492277A patent/JPS5382777A/ja active Granted
- 1977-12-02 GR GR54913A patent/GR64964B/el unknown
- 1977-12-05 AT AT868677A patent/AT357529B/de not_active IP Right Cessation
- 1977-12-05 CS CS778086A patent/CS199694B2/cs unknown
- 1977-12-05 FR FR7736525A patent/FR2372814A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IE772446L (en) | 1978-06-03 |
| FR2372814A1 (fr) | 1978-06-30 |
| JPS6154792B2 (da) | 1986-11-25 |
| SE7713635L (sv) | 1978-06-04 |
| IL53520A (en) | 1981-07-31 |
| GB1588639A (en) | 1981-04-29 |
| AU519994B2 (en) | 1982-01-07 |
| HU175676B (hu) | 1980-09-28 |
| IE46435B1 (en) | 1983-06-15 |
| CA1097657A (en) | 1981-03-17 |
| FR2372814B1 (da) | 1980-10-10 |
| DD133667A5 (de) | 1979-01-17 |
| IT1089341B (it) | 1985-06-18 |
| LU78616A1 (da) | 1978-04-20 |
| ATA868677A (de) | 1979-12-15 |
| AU3117577A (en) | 1979-06-07 |
| AT357529B (de) | 1980-07-10 |
| IL53520A0 (en) | 1978-03-10 |
| CS199694B2 (en) | 1980-07-31 |
| SE441446B (sv) | 1985-10-07 |
| GR64964B (en) | 1980-06-10 |
| JPS5382777A (en) | 1978-07-21 |
| DK149850C (da) | 1987-04-27 |
| CH635578A5 (en) | 1983-04-15 |
| DK536677A (da) | 1978-06-04 |
| NL7713153A (nl) | 1978-06-06 |
| SU888821A3 (ru) | 1981-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK149850B (da) | Analogifremgangsmaade til fremstilling af 5-(3,4-disubst. phenyl)-oxazolidinoner eller thiazolidinoner eller de tilsvarende thioner | |
| KR101344989B1 (ko) | Ppar 작용제 활성을 갖는 유도체 | |
| KR0130976B1 (ko) | 3-[4-(1-치환된-4-피페라지닐)부틸]-4-티아졸리디논, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| SU1424732A3 (ru) | Способ получени 2,4-диамино-5-(замещенных)пиримидинов или их солей | |
| HU214032B (en) | Process for producing benzoisothiazole and benzoisoxazole-3-carboxamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| JPS6040428B2 (ja) | 新規3−アリ−ル−2−オキサゾリジノン誘導体、その製法及び該誘導体を含有する抗抑うつ剤 | |
| EP0343050B1 (fr) | Dérivés de phényl-6 pipérazinyl-alkyl-3 1H,3H-pyrimidinedione-2,4, leur préparation et leur application en thérapeutique | |
| TW201111358A (en) | Anthelmintic agents and their use | |
| CH680440A5 (da) | ||
| DK174867B1 (da) | 1,4-Dihydropyridinderivater, farmaceutiske præparater deraf, anvendelse af forbindelserne til fremstilling af sådanne præparater og fremgangsmåde til fremstilling af forbindelserne | |
| FI91870B (fi) | Menetelmä antidiabeettisina aineina käytettävien bentsoksatsiinijohdannaisten valmistamiseksi | |
| HU207731B (en) | Process for producing aryl-piperazinyl-alkylene-phenyl-p-heterocyclic compounds, pharmaceutically acceptable acid additional salts and pharmaceutical compositions containing them as active components | |
| CZ177892A3 (en) | AMINOMETHYL SUBSTITUTED 2,3-DIHYDROPYRAN(2,3-b)PYRIDINES, PROCESS OF THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | |
| DK154083B (da) | Analogifremgangsmaade til fremstilling af halogenvincamonderivater eller optisk aktive isomere eller syreadditionssalte deraf | |
| KR900005956B1 (ko) | 1,4-디하이드로피리딘-3,5-디카르복실산의 비대칭 에스테르 유도체의 제조방법 | |
| CS216525B2 (en) | Method of making the phenylpiperazine derivatives | |
| FR2634207A1 (fr) | Derives de ((piperidinyl-4)methyl) benzazepines, leur preparation et leur application en therapeutique | |
| EP0632035B1 (fr) | Nouvelles aminoalkylchromones, leur procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
| SU745349A3 (ru) | Фунгицидна композици | |
| EP0205264B1 (en) | Condensed seven-membered heterocyclic compounds, their production and use | |
| US4536578A (en) | 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted)piperazines | |
| JPS6333354A (ja) | デカヒドロナフチ−2−イル−アルキルアミン類 | |
| JPH0435470B2 (da) | ||
| FR2605008A1 (fr) | Derives d'imidazo (4,5-b)pyridinone-2, leur preparation et leur application en therapeutique | |
| EP0351283A1 (fr) | Dérivés de [(pipéridinyl-4) méthyl]-2 dihydro-2,3 1H-isoindole et tétrahydro-2,3,4,5 1H-benzazépines, leur préparation et leur application en thérapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |